Surrozen pauses PhI clinical trial in ulcerative colitis due to adverse events in liver

Paul Schloesser

Associate Editor

Just over a month after Wnt player Surrozen handed off its retinal disease candidate to Boehringer Ingelheim, the San Francisco biotech is reporting clinical issues …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Surrozen pauses PhI clinical trial in ulcerative colitis due to adverse events in liver

Paul Schloesser

Associate Editor

Sign up to read this article for free.

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

CBER's deputy director departs as staff shakeup continues

Eli Lilly stockpiles $548M of oral weight loss drug ahead of launch

Will CRISPR matter?

FDA approves first drug to treat ultra-rare lipid storage disease

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

Sur­rozen paus­es PhI clin­i­cal tri­al in ul­cer­a­tive col­i­tis due to ad­verse events in liv­er

Associate Editor

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Surrozen pauses PhI clinical trial in ulcerative colitis due to adverse events in liver